Joint Formulary & PAD

Levomepromazine - Nausea and vomiting

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Oral solution
  • Tablets
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :
Important

This drug (for this indication) has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to APC.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Levomepromazine
Indication :
Nausea and vomiting
Group Name :
Keywords :
Refractory nausea and vomiting
Brand Names Include :
Levorol
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Levomepromazine is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Nausea and vomiting .

Committee Recommendations (1)

25 Jun 24 - Not Set

Excluding palliative care.

Tablets 6.25mg and Oral solution 5mg/ml

This drug has not yet been assessed for formulary status [for 2nd/3rd line refractory nausea and vomiting] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.